What is a stock summary page? Click here for an overview.
Business Description
Clene Inc
NAICS : 311999
SIC : 2834
ISIN : US1856341029
Share Class Description:
CLNN: Ordinary SharesCompare
Compare
Traded in other countries / regions
CLNN.USA84C0.Germany Index Membership
Russell 2000 IPO Date
2020-12-31Description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.58 | |||||
| Equity-to-Asset | -0.32 | |||||
| Debt-to-Equity | -2.35 | |||||
| Debt-to-EBITDA | -0.62 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -18.04 | |||||
| Beneish M-Score | -5.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.7 | |||||
| 3-Year EBITDA Growth Rate | -21.4 | |||||
| 3-Year EPS without NRI Growth Rate | 29.1 | |||||
| 3-Year FCF Growth Rate | 36 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 625.85 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.15 | |||||
| 9-Day RSI | 35.96 | |||||
| 14-Day RSI | 36.81 | |||||
| 3-1 Month Momentum % | -33.55 | |||||
| 6-1 Month Momentum % | -37.14 | |||||
| 12-1 Month Momentum % | -61.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | |||||
| Quick Ratio | 1.56 | |||||
| Cash Ratio | 1.18 | |||||
| Days Inventory | 320.16 | |||||
| Days Sales Outstanding | 96.41 | |||||
| Days Payable | 7438.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.4 | |||||
| Shareholder Yield % | -18.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.53 | |||||
| Operating Margin % | -9349.42 | |||||
| Net Margin % | -11520.47 | |||||
| FCF Margin % | -5502.57 | |||||
| ROE % | -4726.49 | |||||
| ROA % | -100.18 | |||||
| ROIC % | -100.31 | |||||
| 3-Year ROIIC % | 148.62 | |||||
| ROC (Joel Greenblatt) % | -286.69 | |||||
| ROCE % | -213.01 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 53.6 | |||||
| EV-to-EBIT | -1.37 | |||||
| EV-to-Forward-EBIT | -1.86 | |||||
| EV-to-EBITDA | -1.46 | |||||
| EV-to-Forward-EBITDA | -1.86 | |||||
| EV-to-Revenue | 100.48 | |||||
| EV-to-Forward-Revenue | 150.75 | |||||
| EV-to-FCF | -1.63 | |||||
| Price-to-GF-Value | 0.64 | |||||
| Earnings Yield (Greenblatt) % | -72.99 | |||||
| FCF Yield % | -81.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CLNN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Clene Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.35 | ||
| EPS (TTM) ($) | -4.04 | ||
| Beta | 0.14 | ||
| 3-Year Sharpe Ratio | -0.6 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 84.78 | ||
| 14-Day RSI | 36.81 | ||
| 14-Day ATR ($) | 0.242619 | ||
| 20-Day SMA ($) | 2.8995 | ||
| 12-1 Month Momentum % | -61.23 | ||
| 52-Week Range ($) | 2.55 - 9.2 | ||
| Shares Outstanding (Mil) | 8.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clene Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Clene Inc Frequently Asked Questions
What is Clene Inc(CLNN)'s stock price today?
The current price of CLNN is $2.63. The 52 week high of CLNN is $9.20 and 52 week low is $2.55.
When is next earnings date of Clene Inc(CLNN)?
The next earnings date of Clene Inc(CLNN) is 2025-08-07 Est..
Does Clene Inc(CLNN) pay dividends? If so, how much?
Clene Inc(CLNN) does not pay dividend.
Guru Commentaries on NAS:CLNN
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers